# Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05425940/  
OnCo record `nct05425940` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zanzalintinib, Atezolizumab, Regorafenib in colorectal cancer, run by Exelixis, active and no longer recruiting.

## Summary

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05425940 by Exelixis, with 901 participants enrolled, started 2022-09-07 and due to reach its primary completion in 2026-06-16. Interventions recorded: XL092, Atezolizumab, Regorafenib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05425940
- Phase: 3
- Setting: A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Sponsor: Exelixis
- Enrolled: 901

## Sources

- ClinicalTrials.gov NCT05425940: https://clinicaltrials.gov/study/NCT05425940

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)

---
JSON: https://onco.cc/api/v1/entities/nct05425940.json